PMID- 29340015
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 67
DP  - 2017 Dec 19
TI  - Apatinib alone or combined with radiotherapy in metastatic prostate cancer: 
      Results from a pilot, multicenter study.
PG  - 110774-110784
LID - 10.18632/oncotarget.22719 [doi]
AB  - BACKGROUND: To study safety and efficacy of apatinib in combination of 
      radiotherapy in patients with symptomatic bony disease prostate cancer(SBPC), 
      based on the potential synergistic antitumor activity between apatinib and 
      Radiation Therapy (RT). PATIENTS AND METHODS: In phase I dose escalation part, 18 
      patients received apatinib dose at 250 mg every other day, 250 mg daily and 500 
      mg daily. In phase II part, the 250 mg daily cohorts were expanded to 20 patients 
      in combination of RT (6 Gy/fraction, 5 fraction in total), one patient lost 
      followed up and excluded the study, comparing with RT alone cohort with 10 
      patients, ratio of RT to RT + apatinib was 1 to 2. Evaluations included adverse 
      events (AEs), prostate specific antigen (PSA) changes, radiographic evaluation 
      and pain relief. RESULTS: In phase I study, common apatinib-related AEs (arAEs) 
      were fatigue, anorexia, hand foot syndrome, proteinuria, and hypertension (HTN). 
      Grade 3arAEs included HTN, proteinuria, liver dysfunction. In phase II study, 
      combination apatinib with RT cohorts, AEs events increased comparing with either 
      apatinib alone or RT alone; at the same time, combination cohorts showed PSA 
      declines of >/=50% in 12 patients, and stable disease in 6 patients. Combination 
      cohorts had pain control significantly improved in both level and duration 
      comparing with RT alone. CONCLUSIONS: In SBPC patients, apatinib at less than 500 
      mg daily dose as mono-therapy had tolerable toxicity. Apatinib at dose of 250 mg 
      daily in combining with RT synergized pain control, the overall AEs were 
      manageable. Further studies are needed in large sample size future trials.
FAU - Zhao, Feng
AU  - Zhao F
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 
      Sichuan, PR China.
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
FAU - Tian, Wei
AU  - Tian W
AD  - Operations Management Department, Hospital of University of Electronic Science 
      and Technology of China and Sichuan Provincial People's Hospital, Chengdu, 
      Sichuan, PR China.
AD  - School of Medicine, University of Electronic Science and Technology of China, 
      Chengdu, Sichuan, PR China.
FAU - Zeng, Ming
AU  - Zeng M
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
AD  - School of Medicine, University of Electronic Science and Technology of China, 
      Chengdu, Sichuan, PR China.
FAU - Xia, Jianling
AU  - Xia J
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
FAU - Hu, Honglin
AU  - Hu H
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
FAU - Hao, Xinbao
AU  - Hao X
AD  - Sino-America Cancer Center, Hainan Medial University, Haikou, Hainan, PR China.
FAU - Han, Liangfu
AU  - Han L
AD  - Department of Radiation Oncology, ChangAn Hospital, Xi'an, Shanxi, PR China.
FAU - Liu, Hao
AU  - Liu H
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
FAU - He, Yangke
AU  - He Y
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
FAU - Zhu, Xueqiang
AU  - Zhu X
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
FAU - Liang, Liang
AU  - Liang L
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
FAU - Ao, Rui
AU  - Ao R
AD  - Cancer Center Hospital of University of Electronic Science and Technology of 
      China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China.
FAU - Wei, Min
AU  - Wei M
AD  - Ziyang People's Hospital, Sichuan, Ziyang, Sichuan, PR China.
FAU - Deng, Lili
AU  - Deng L
AD  - Sichuan Friendship Hospital, Chengdu, Sichuan, PR China.
FAU - Wei, Yuquan
AU  - Wei Y
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 
      Sichuan, PR China.
LA  - eng
PT  - Journal Article
DEP - 20171128
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5762283
OTO - NOTNLM
OT  - PSA
OT  - adverse events
OT  - apatinib
OT  - metastatic prostate cancer
OT  - radiotherapy
COIS- CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:01
PMCR- 2017/12/19
CRDT- 2018/01/18 06:00
PHST- 2017/03/01 00:00 [received]
PHST- 2017/10/13 00:00 [accepted]
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:01 [medline]
PHST- 2017/12/19 00:00 [pmc-release]
AID - 22719 [pii]
AID - 10.18632/oncotarget.22719 [doi]
PST - epublish
SO  - Oncotarget. 2017 Nov 28;8(67):110774-110784. doi: 10.18632/oncotarget.22719. 
      eCollection 2017 Dec 19.